sb 202190 has been researched along with Cancer of the Thyroid in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Falola, J | 1 |
| Zhu, X | 1 |
| Gu, Y | 1 |
| Kim, LT | 1 |
| Sarosi, GA | 1 |
| Anthony, T | 1 |
| Nwariaku, FE | 1 |
1 other study available for sb 202190 and Cancer of the Thyroid
| Article | Year |
|---|---|
Antiproliferative effects of Src inhibition on medullary thyroid cancer.
Topics: Apoptosis; Carcinoma, Medullary; Cell Division; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Enzym | 2004 |